AbCellera Biologics (ABCL) Revenue: 2020-2023
Historic Revenue for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $9.2 million.
- AbCellera Biologics' Revenue fell 57.40% to $9.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $38.0 million, marking a year-over-year decrease of 92.17%. This contributed to the annual value of $28.8 million for FY2024, which is 24.17% down from last year.
- Per AbCellera Biologics' latest filing, its Revenue stood at $9.2 million for Q4 2023, which was up 39.10% from $6.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Revenue registered a high of $316.6 million during Q1 2022, and its lowest value of $4.7 million during Q1 2020.
- Moreover, its 3-year median value for Revenue was $24.6 million (2021), whereas its average is $74.9 million.
- Per our database at Business Quant, AbCellera Biologics' Revenue soared by 4,253.47% in 2021 and then crashed by 96.15% in 2023.
- AbCellera Biologics' Revenue (Quarterly) stood at $207.9 million in 2020, then slumped by 32.98% to $139.3 million in 2021, then tumbled by 84.54% to $21.5 million in 2022, then tumbled by 57.40% to $9.2 million in 2023.
- Its Revenue stands at $9.2 million for Q4 2023, versus $6.6 million for Q3 2023 and $10.1 million for Q2 2023.